medigraphic.com
ISSN 1405-8871 (Print)

2026, Number 1

<< Back Next >>

Aten Fam 2026; 33 (1)

Assessment of Medical Knowledge on Cannabinoid-Based Medicine

Millán-Guevara JD, Olivas-Villa M, Amézquita-López BA, Flores-Mendoza IB, Moreno-Zazueta JN, Quiñonez-Bastidas GN

Language: Spanish
References: 30
Page: 24-32
PDF size: 180.51 Kb.


ABSTRACT

Objective: To assess the knowledge of medical residents regarding cannabinoid- derived medicine. Methods: An anonymous survey administered to professionals affiliated to medical specialty programs of the Center for Research and Teaching in Health Sciences at the Autonomous University of Sinaloa, based at the Civil Hospital of Culiacán. Results: Of the 71 medical residents surveyed, 93% recognized the medical use of cannabinoids, but 77.5% did not receive professional training on the subject. Consequently, 83.1% did not feel prepared to prescribe them, and 23.9% lacked knowledge about the endocannabinoid system. Additionally, 93% considered medical training in this field necessary. Regarding regulation, 88.7% were unfamiliar with the Reglamento de la Ley General de Salud en Materia de Control Sanitario para la Producción, Investigación y Uso Medicinal de la Cannabis y sus Derivados Farmacológicos (Regulation of the General Health Law on Sanitary Control for the Production, Research, and Medicinal Use of Cannabis and its Pharmacological Derivatives). Conclusion: There is a broad acceptance of the therapeutic use of cannabinoids; however, insufficient training and an unawareness normative among the surveyed medical residents highlight the need to strengthen education in cannabinoid medicine as an emerging theme in Mexico.


REFERENCES

  1. Schievenini JD, Pérez RC. Pasado y presente de losusos medicinales del cannabis en México. Redes. 2020;26(50):115–45.

  2. Academia Farmacéutica de México (1846). [Internet].[citado 2023 Sep 5]. Disponible en:https://books.google.es/books?hl=es&lr=&id=rz4-sAQAAMAAJ&oi=fnd&pg=IA5&dq=farmacopea+mexicana+1846&ots=KYD-BPVE0s&sig=kWuuS-x_FADNvBj6vhU90daiUY8#v=onepage&q=cannabis&f=false

  3. Álvarez-Roldán A, Gamella JF, Parra I. La legalizacióndel cannabis: un experimento americano deconsecuencias globales. Revista Española de Drogodependencias.2018;43(4):22-38.

  4. de Souza MR, Henriques AT, Limberger RP. Medicalcannabis regulation: an overview of modelsaround the world with emphasis on the Brazilianscenario. J Cannabis Res. 2022;4(1):33.

  5. Presidencia de la República. Diario Oficial de laFederación. 2021 Reglamento de la Ley Generalde Salud en Materia de Control Sanitario parala Producción, Investigación y Uso Medicinalde la Cannabis y sus Derivados Farmacológicos[Internet]. [citado 2023 Sep 3]. Disponible en:https://dof.gob.mx/nota_detalle.php codigo=5609709&fecha=12/01/2021#gsc.tab=0

  6. Weisman JM, Rodríguez M. A systematic reviewof medical students’ and professionals’attitudes and knowledge regarding medical cannabis.J Cannabis Res. 2021;3(1):47.

  7. Zolotov Y, Metri S, Calabria E, Kogan M.Medical cannabis education among healthcaretrainees: A scoping review. Complement TherMed. 2021;58:102675.

  8. Abuhasira R, Schleider LBL, Mechoulam R,Novack V. Epidemiological characteristics,safety and efficacy of medical cannabis in theelderly. Eur J Intern Med. 2018;49:44–50.

  9. Dos Santos RG, Hallak JEC, Crippa JAS. NeuropharmacologicalEffects of the Main Phytocannabinoids:A Narrative Review.Adv ExpMed Biol. 2021;1264:29-45.

  10. Artukoglu BB, Bloch MH. The Potential ofCannabinoid-Based Treatments in TouretteSyndrome. CNS Drugs. 2019;33(5):417–30.

  11. Coghe G, Pau M, Corona F, Frau J, LoreficeL, Fenu G, et al. Walking improvements withnabiximols in patients with multiple sclerosis. JNeurol. 2015;262(11):2472–7.

  12. Müller-Vahl KR. Treatment of Tourette syndromewith cannabinoids. Behavioural Neurology.2013;27(1):119–24.

  13. McGuire P, Robson P, Cubala WJ, Vasile D,Morrison PD, Barron R, et al. Cannabidiol(CBD) as an Adjunctive Therapy in Schizophrenia:A Multicenter Randomized ControlledTrial. Am J Psychiatry. 2018;175(3):225–31.

  14. Ranum RM, Whipple MO, Croghan I, Bauer B,Toussaint LL, Vincent A. Use of Cannabidiol inthe Management of Insomnia: A Systematic Review.Cannabis Cannabinoid Res. 2023;8(2):213-229.

  15. Hordowicz M, Jarosz J, Czaplińska M, LeonhardA, Klimkiewicz A. Polish Physicians’ Perspectiveson Medical Cannabis Policy and Educational Needs:Results of An Online Survey. J Clin Med.2021;10(19):4545.

  16. Hordowicz M, Klimkiewicz A, Jarosz J, WysockaM, Jastrzębska M. Knowledge, attitudes, andprescribing patterns of cannabis and cannabinoid-containing medicines among Europeanhealthcare workers: a systematic literature review.Drug Alcohol Depend. 2021;221:108652.

  17. Syed SA, Singh J, Elkholy H, Palavra IR, TomicevicM, Eric AP, et al. International perspectiveon physician knowledge, attitude and practicesrelated to medical cannabis. medRxiv [Preprint].2023 Jul 27:2023.07.26.23293157.

  18. Isralowitz R, Reznik A, Zolotov Y, Grinstein-CohenO, Wacht O, Pruginin I, et al. Toward medicalcannabis education in Israel. ComplementTher Med. 2021;58:102709.

  19. Gardiner KM, Singleton JA, Sheridan J, KyleGJ, Nissen LM. Health professional beliefs,knowledge, and concerns surrounding medicinalcannabis – A systematic review. PLoS One. 2019;14(5):e0216556.

  20. Sideris A, Khan F, Boltunova A, Cuff G, GhariboC, Doan LV. New York Physicians’ Perspectivesand Knowledge of the State MedicalMarijuana Program. Cannabis Cannabinoid Res.2018;3(1):74–84.

  21. Cohen K, Weizman A, Weinstein A. Positiveand Negative Effects of Cannabis and Cannabinoidson Health. Clin Pharmacol Ther.2019;105(5):1139–47.

  22. Ziemianski D, Capler R, Tekanoff R, Lacasse A,Luconi F, Ware MA. Cannabis in medicine: a nationaleducational needs assessment among Canadianphysicians. BMC Med Educ. 2015;15(1):52.

  23. Häuser W, Finn DP, Kalso E, Krcevski-SkvarcN, Kress HG, Morlion B, et al. European PainFederation (EFIC) position paper on appropriateuse of cannabis-based medicines and medical cannabisfor chronic pain management. Eur J Pain.2018;22(9):1547–64.

  24. Observatorio Europeo de las Drogas y las Toxicómanas.Uso médico del cannabis y los cannabinoides:preguntas y respuestas para la elaboraciónde políticas [Internet]. [citado 2023Ago 24]. Disponible en: http://hdl.handle.net/10234/187911.

  25. Ashton CH. Adverse effects of cannabis and cannabinoids.Br J Anaesth. 1999;83(4):637–49.

  26. Barrett FS, Schlienz NJ, Lembeck N, Waqas M,Vandrey R. “Hallucinations” Following AcuteCannabis Dosing: A Case Report and Comparisonto Other Hallucinogenic Drugs. CannabisCannabinoid Res. 2018;3(1):85–93.

  27. LaFrance EM, Stueber A, Glodosky NC, MauzayD, Cuttler C. Overbaked: assessing and predictingacute adverse reactions to Cannabis. J CannabisRes. 2020;2(1):3.

  28. Hjorthøj C, Compton W, Starzer M, NordholmD, Einstein E, Erlangsen A, et al. Association betweencannabis use disorder and schizophreniastronger in young males than in females. PsycholMed. 2023; 53(15):7322-7328.

  29. González-González M del R, Yeverino-GutiérrezML, González-Santiago O. Attitudes toward medicinalmarijuana in metropolitan Monterrey,Mexico. Salud Publica Mex. 2018;60(2):120–2.

  30. Camberos-Barraza J, Osuna-Ramos JF, Rábago-Monzón AR, Quiñonez-Angulo LF, González-Peña HR, Pérez-Ramos AA, et al. Scientificfacts improve cannabis perception and publicopinion: results from Sinaloa, México. Sci Rep.2023;13(1):17318.Millán-Guevara JD y cols.Aten Fam. 2026;33(1):24-32. http://dx.doi.org/10.22201/fm.14058871p.2026.1.94008




2020     |     www.medigraphic.com